Company Overview and News

0
SCOR: Half-year statement of the liquidity contract between SCOR SE and EXANE BNP Paribas

2018-07-13 globenewswire
As per the liquidity contract granted by SCOR SE to EXANE BNP PARIBAS, as at 30 June 2018 the following assets appeared on the liquidity account:
SCR

0
SCOR : Bilan semestriel du contrat de liquidité SCOR SE avec la société EXANE BNP Paribas

2018-07-13 globenewswire
Au titre du contrat de liquidité confié par la société SCOR à EXANE BNP PARIBAS, en date de dénouement du 30 juin 2018, les moyens suivants figuraient au compte de liquidité :
SCR

0
UPDATE 1-U.S. rejects French request for Iran exemptions as reinsurer Scor pulls out

2018-07-13 reuters
PARIS (Reuters) - The United States has rejected a French request for waivers for its companies operating in Iran that Paris sought after President Donald Trump imposed sanctions on the Islamic Republic, French Finance Minister Bruno Le Maire told Le Figaro.
SCR

0
Coming Soon: An Improved Estimate Of Your Longevity - Financial Advisors' Daily Digest

2018-05-23 seekingalpha
Replacing your chronological age with your biological age as a retirement plan input could help you improve decisions on how to save, invest and spend.
SCR

0
SCOR : Toutes les résolutions proposées ont été adoptées par l'Assemblée Générale Mixte de SCOR du 26 avril 2018

2018-04-26 globenewswire
Toutes les résolutions proposées ont été adoptées par l'Assemblée Générale Mixte de SCOR du 26 avril 2018
SCR

0
SCOR's combined general meeting of April 26, 2018 adopts all the proposed resolutions

2018-04-26 globenewswire
The Combined General Meeting of SCOR SE was held on April 26, 2018 in Paris and was chaired by Mr. Denis Kessler, Chairman and Chief Executive Officer of SCOR SE.
SCR

0
SCOR : ASSEMBLEE GENERALE MIXTE DU 26 AVRIL 2018 - MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES

2018-03-21 globenewswire
Les actionnaires de la Société sont invités à participer à l'Assemblée Générale Mixte qui se tiendra le :
SCR

0
SCOR: COMBINED SHAREHOLDERS' MEETING TO BE HELD ON APRIL 26, 2018 - AVAILABILITY OF THE DOCUMENTS RELATING TO THE 2018 COMBINED SHAREHOLDERS' MEETING

2018-03-21 globenewswire
Thursday, April 26, 2018 at 10:00 at the headquarters of SCOR SE 5, avenue Kléber 75016 Paris
SCR

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EPA:SCR / SCOR SE on message board site Silicon Investor.

Philadelphia Sports Scrapbook Describe the Current Administration in One Word
MDRX: Allscripts, Inc. Canadian Prescription Drugs
Screening for Stocks WSCRF - North American Nickel (NAN.V)
Screening Criteria for Preferreds SliderOnTheBlack - Trading Guru or Unscrupulous Villain?
Stock screener Stock screener